IRulya Therapeutics Inc. IRLA
38.33 USD -0.29 (-0.75%)
At closeNov 11, 2026, 4:00 PM EST
38.33 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
38.33 Day range 45.00
15.10 52-week range 910.00
- YTD
- -94.28%
- 1 year
- -89.29%
News
globenewswire.com IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NEW HAVEN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
globenewswire.com IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying…
defenseworld.net Quince Therapeutics (NASDAQ: QNCX) renames itself IRulya and sets IRLA ticker What happened Quince Therapeutics, Inc. (NASDAQ: QNCX) said it changed its name to IRulya Therapeutics Inc. effective at 4:01 p.m. Eastern Time on October 9, 2026. The common stock is expected to…
globenewswire.com Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO…
defenseworld.net Quince Therapeutics Stockholders Approve PIPE, Share Increase and Equity Plans Quince Therapeutics (NASDAQ: QNCX) stockholders approved five proposals at the company's Oct. 6, 2026 special meeting, including measures related to the conversion of preferred stock, a private…
seekingalpha.com Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
seekingalpha.com Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
globenewswire.com Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026 SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease…
globenewswire.com Quince Therapeutics to Participate in September 2026 Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease…
globenewswire.com Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
globenewswire.com Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board SOUTH SAN FRANCISCO, Calif. , June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease…
seekingalpha.com Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
seekingalpha.com Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript
globenewswire.com UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR…
globenewswire.com Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced it has acquired Orphai Therapeutics Inc., a clinical-stage biotechnology company. The…
globenewswire.com Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR…
businesswire.com Quince Therapeutics Settles Approximately $16.4 Million of Debt SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company's outstanding obligations under its…
defenseworld.net Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Reduce” by Analysts Shares of Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) have earned a consensus recommendation of "Reduce" from the seven analysts that are presently covering the company, Marketbeat.com…
defenseworld.net Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Reduce” by Analysts Shares of Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) have received an average rating of "Reduce" from the nine brokerages that are currently covering the stock, MarketBeat Ratings…